Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Surrozen, Inc./DE (SRZN)

Surrozen gets FDA IND clearance for SZN-8141, triggers $95.1 million second closing

Positive Impact 4 of 5 financing Written later

Surrozen said the FDA cleared its Investigational New Drug application for SZN-8141, a treatment for diabetic macular edema, allowing clinical development to advance. The clearance satisfies a milestone for the second closing of its March 2025 private placement, which is expected to bring about $95.1 million in gross proceeds on or about October 20, 2026, before placement agent fees and other expenses.

Key points

  • FDA clearance of the SZN-8141 IND took effect after the statutory 30-day review period, announced October 2, 2026
  • First patient dosing in the Phase 1b/2a DUET study is expected in Q4 2026, with initial data expected in 2H 2027
  • Second closing of the March 2025 two-tranche private placement expected on or about October 20, 2026, with approximately $95.1 million in gross proceeds
  • Surrozen must file a Form S-3 resale registration statement within 30 calendar days after the closing

The filing

CompanySurrozen, Inc./DE (SRZN)
Form8-K, current report
Filed with the SECOct 2, 2026, 8:05 AM ET
Accession number0001193125-26-411298

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 02, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.